	100 mm	
260 mm	<page-header><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></page-header>	<text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text><text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text></text>
	<ul> <li>Patients are consensitive to numain normal immunoglobulin, by inst injecting the product slowly</li> <li>Patients are carefully monitored for any symptoms throughout the infusion period. In paticular, patients naive to human normal immunoglobulin, patients switched from an alternative product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. All other patients should be observed for at least 20 minutes after administration.</li> <li>Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment should be implemented.</li> <li>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection and the inclusion of effective manufacturing steps for inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood</li> </ul>	
	Front Side	Deals Side

Front Side

Back Side

Reason for revision : As per change control no. CBL/CCF/2020/0055Artwork No.:									
Supersedes No.: AW-053-01									
	Prepared by	Reviewed by					Approved by		
Department	QA	Production	Regulatory	Marketing	Medical	QA	QA		
Sign									
Date									
Name									
Designation									

Product Name: Globucel - SC Leaflet Size: 100 x 260 mm GSM: 50 gsm+/- 10 % Type of paper: Maplitho

Fold Size: ~50 x ~32.5 mm No. of fold: 4 Colour shade: Black 040220